Acute Bipolar Depression: A Review of the Use of Olanzapine/Fluoxetine

  title={Acute Bipolar Depression: A Review of the Use of Olanzapine/Fluoxetine},
  author={William V. Bobo and Richard A. Epstein and Richard Charles Shelton},
Depression is the predominant mood state in patients with bipolar I or II disorder over the course of illness. In spite of this, relatively few pharmacological treatments have been shown to be effective for treating depressive episodes associated with bipolar disorder in adults. Combination therapy with olanzapine and fluoxetine (OFC) is approved in the US for the treatment of acute depressive episodes in adults with bipolar I disorder. The short-term efficacy and safety of OFC for the… Expand
Efficacy and safety of fluoxetine monotherapy in bipolar depression: a systematic review
Fluoxetine showed to be efficacious in bipolar depression, confirming its well-known activity in major depressive episodes, with a low percentage of mood switch, despite the general view that antidepressants may increase the rate of manic/hypomanic episodes in BDs. Expand
Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults
  • W. Bobo
  • Medicine
  • Expert review of clinical pharmacology
  • 2013
For each drug, comparative and real-world effectiveness studies are lacking, as are effectiveness and safety data in elderly, young and pregnant/nursing patients, and the exact place of iloperidone, asenapine and lurasidone within the broader antipsychotic armamentarium is currently difficult to establish. Expand


Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.
Olanzapine is more effective than placebo, and combined olanzapine-fluoxetine isMore effective than olanZapine and placebo in the treatment of bipolar I depression without increased risk of developing manic symptoms. Expand
Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data
The efficacy and safety data for fluoxetine + olanzapine in treatment-resistant depression (TRD) in FLX + OLZ was generally well tolerated; however, increases in body weight and prolactin levels with FLX / OLZ were greater than that of antidepressant monotherapy groups and were similar to OLZ monotherapy. Expand
Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues
The FLX/OLZ combination was well-tolerated; however, body weight gain and increases in prolactin were greater than that of the antidepressant monotherapy groups, and were comparable to that of OLZ monotherapy. Expand
The use of antidepressants in bipolar disorder.
There is a place for antidepressants in bipolar disorder; however, it is important to be cautious and evaluate their use on a case-by-case basis. Expand
Treatment of bipolar depression: an update.
Bipolar depression seems to be a more difficult condition to treat than mania, most patients need complex combination treatment although the published evidence on this type of treatment is limited. Expand
Effectiveness of adjunctive antidepressant treatment for bipolar depression.
The use of adjunctive, standard antidepressant medication, as compared with the use of mood stabilizers, was not associated with increased efficacy or with increased risk of treatment-emergent affective switch. Expand
A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers.
Paroxetine and venlafaxine are both effective and safe in the treatment of depressive breakthrough episodes in bipolar disorder and there was a suggestion of a slightly higher risk for switch to mania or hypomania with venl Lafaxine. Expand
Risperidone and paroxetine given singly and in combination for bipolar depression.
It is suggested that risperidone, paroxetine, and the combination of ris peridone and paroxETine are equally but modestly effective when added to a mood stabilizer in bipolar depression. Expand
Bipolar rapid cycling: focus on depression as its hallmark.
Preliminary data suggest that the combination of lithium and divalproex sodium administered continuously over 6 months appears to result in marked acute and continuation antimanic efficacy in 85% of patients and marked antidepressant efficacy in 60%. Expand
Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: results of an 8‐week open label trial
Olanzapine may be an effective, well‐tolerated option for treating acute non‐psychotic depression across a variety of bipolar disorder subtypes. Expand